Clinical Trials Logo
  1. Home
  2. Severe Combined Immunodeficiency
  3. NCT00152100

Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome

Severe Combined Immunodeficiency Clinical Trial

Official title:
Transplantation of Highly Purified Haploidentical CD133 Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome

Clinical Trial Summary

Treatment for severe combined immunodeficiency (SCID) is a medical emergency. A stem cell transplant (immature blood cells that can make other blood cells) from a (MSD) matched sibling donor (brother or sister who is a "match" for your child's immune (HLA) type), usually results in complete correction of immune function. However, most patients lack a matched sibling donor, requiring the use of an alternate donor source.

Transplantation of cells from haploidentical family donors (typically parents) has resulted in immune system correction in the majority of SCID individuals. However, only 65-80% of patients survive greater than one year after this procedure. Failure results from life-threatening infections, graft versus host disease (GvHD) or post-transplant treatment-related effects. Also, for patients that survive beyond one year, B-cell (type of blood cell that fights infection) and natural killer cell function (cell that attacks infections and cancer cells) frequently fail to work, resulting in the need for long-term treatment with intravenous gamma-globulin (IVIg).

In this study, in an effort to restore the overall cell function in patients with SCID, researchers will use a highly purified CD133+ hematopoietic cell graft (stem cell transplant without many mature donor white cells, called T-cells) obtained via use of the Miltenyi CliniMACS device, a device not FDA approved.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00152100
Study type Interventional
Source St. Jude Children's Research Hospital
Contact
Status Completed
Phase Phase 1
Start date February 2004
Completion date August 2007
View Details
See also
  Status Clinical Trial Phase
Completed NCT00006335 - Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID N/A
Not yet recruiting NCT02231983 - Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China N/A
Active, not recruiting NCT03597594 - Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Phase 1/Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00001255 - Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study N/A
Recruiting NCT05651113 - The Experience of Screening for SCID
Completed NCT00794508 - MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Phase 2
Recruiting NCT03538899 - Autologous Gene Therapy for Artemis-Deficient SCID Phase 1/Phase 2
Recruiting NCT05298930 - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00845416 - Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Completed NCT03878069 - Registry Study of Revcovi Treatment in Patients With ADA-SCID
Recruiting NCT01019876 - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Phase 2/Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Withdrawn NCT02177760 - Sirolimus Prophylaxis for aGVHD in TME SCID Phase 2
Recruiting NCT00695279 - Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Completed NCT01420627 - EZN-2279 in Patients With ADA-SCID Phase 3
Terminated NCT02127892 - SCID Bu/Flu/ATG Study With T Cell Depletion Phase 1/Phase 2
Completed NCT04246840 - Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft